Adding local consolidative therapy after induction treatment with nivolumab plus ipilimumab does not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer, including those with oligometastatic disease, according to phase III trial results presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer. The findings challenge long-held assumptions about combining radiation or surgery with dual immunotherapy in advanced lung cancer cases.
LONESTAR Trial Design and Patient Population
The open-label, single-center, randomized Phase III LONESTAR trial tested whether reducing residual tumor burden with radiation or surgery after dual immunotherapy could improve systemic disease control in immunotherapy-naive patients. According to data presented at the conference, the study enrolled 166 patients with metastatic non-small cell lung cancer who experienced no disease progression or dose-limiting toxicity after receiving 12 weeks of induction nivolumab plus ipilimumab.
Patients were randomized evenly, with 83 individuals assigned to continue nivolumab and ipilimumab alone and 83 assigned to receive local consolidative therapy followed by the same immunotherapy regimen. Within the consolidation arm, 71 patients received radiation to at least one disease site, while 16 patients underwent surgery when feasible. Out of the total randomized cohort, 77 patients presented with oligometastatic disease.
Did you know?
While local consolidative therapy has historically improved outcomes in selected oligometastatic non-small cell lung cancer patients treated with chemotherapy, its specific benefit alongside immune checkpoint inhibitors has remained uncertain until now, as noted by the International Association for the Study of Lung Cancer.
Survival Outcomes and Statistical Results
At the data cutoff of June 15, 2026, researchers found no significant survival advantage for the addition of radiation or surgery following induction immunotherapy. In the overall randomized population, the median overall survival reached 52.8 months for patients receiving nivolumab and ipilimumab alone, compared to 43.2 months for those who received local consolidative therapy plus the immunotherapy regimen, yielding a hazard ratio of 1.14 and a P-value of .54, according to trial data.
Median progression-free survival in the overall population stood at 24.3 months with immunotherapy alone versus 31.3 months with the addition of local consolidative therapy, with a hazard ratio of 0.79 and a P-value of .22. Among the subgroup of patients with oligometastatic disease, median overall survival reached 75.8 months with nivolumab and ipilimumab alone, compared to 42 months for the consolidative therapy arm. Progression-free survival in this oligometastatic subset was 44.0 months versus 35.7 months, respectively.
“In this randomized trial, adding local consolidative therapy after induction dual checkpoint blockade was feasible, but it did not improve overall survival or progression-free survival in the overall population or among patients with oligometastatic disease,” said Mehmet Altan, M.D., from the MD Anderson Cancer Center in Houston, Texas, according to the International Association for the Study of Lung Cancer.
Adverse Events and Treatment Tolerability
Adding local consolidative therapy did not increase the overall incidence of grade 3 or higher adverse events in the trial. However, investigators observed that pneumonitis occurred numerically more frequently in the consolidation arm, affecting 9.5% of patients compared to 4.9% in the group receiving nivolumab and ipilimumab alone.
Furthermore, trial investigators noted markedly lower absolute lymphocyte counts when systemic therapy was restarted in patients who underwent local consolidative therapy. Despite these physiological changes, the overall safety profile demonstrated that integrating radiation or surgery after dual checkpoint blockade remains clinically feasible.
Frequently Asked Questions
What is local consolidative therapy in lung cancer treatment?
Local consolidative therapy involves using treatments like targeted radiation therapy or surgery to address remaining visible tumors after initial systemic treatment.
What drugs were used in the induction phase of the LONESTAR trial?
Patients received a 12-week induction regimen consisting of the immune checkpoint inhibitors nivolumab combined with ipilimumab.
Did the trial include patients with oligometastatic disease?
Yes, 77 of the 166 randomized patients had oligometastatic disease at the time of randomization, according to trial data presented at the WCLC.
Related reading